Thyrogen Evrópusambandið - íslenska - EMA (European Medicines Agency)

thyrogen

sanofi b.v. - thyrotropin alfa - skjaldkirtilsæxli - fremri sterum stærra hormón og hliðstæðum, sterum og undirstúku hormón og hliðstæðum - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Estring Leggangainnlegg 7,5 míkróg/24 klst. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

estring leggangainnlegg 7,5 míkróg/24 klst.

pfizer aps - estradiol - leggangainnlegg - 7,5 míkróg/24 klst.

Vivelle dot Forðaplástur 100 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 100 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 100 míkróg

Vivelle dot Forðaplástur 25 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 25 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 25 míkróg

Vivelle dot Forðaplástur 37,5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 37,5 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg

Vivelle dot Forðaplástur 50 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 50 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg

Vivelle dot Forðaplástur 75 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 75 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg

Parkódín Filmuhúðuð tafla 500 mg/10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

parkódín filmuhúðuð tafla 500 mg/10 mg

teva b.v.* - paracetamolum inn; codeini phosphas hemihydricus - filmuhúðuð tafla - 500 mg/10 mg

Parkódín forte Filmuhúðuð tafla 500 mg/30 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

parkódín forte filmuhúðuð tafla 500 mg/30 mg

teva b.v.* - paracetamolum inn; codeini phosphas hemihydricus - filmuhúðuð tafla - 500 mg/30 mg

Suvaxyn CSF Marker Evrópusambandið - íslenska - EMA (European Medicines Agency)

suvaxyn csf marker

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - svín - fyrir virkan ónæmingu svína frá 7 vikna aldri til að koma í veg fyrir dauðsföll og draga úr sýkingu og sjúkdómum af völdum svínapestarveiru (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.